Status:
COMPLETED
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Prostate Cancer
Eligibility:
MALE
40+ years
Brief Summary
Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical ...
Eligibility Criteria
Inclusion
- Patients with diagnosis of advanced prostate cancer
- Patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks
- Patients capable of signing ICF
Exclusion
- Patients with hypersensitivity to bicalutamide
- Patients on therapy with terfenadin, astemizol or cisapride
- Participation in a clinical study during the last 30 days
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT00871585
Start Date
March 1 2009
End Date
January 1 2010
Last Update
April 15 2010
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Čakovec, Croatia
2
Research Site
Dubrovnik, Croatia
3
Research Site
Karlovac, Croatia
4
Research Site
Pula, Croatia